The Patient’s Perspective on Major Depressive Disorder: What Do We Know?

Susan Ball, Ph.D.
Cecilia Dedios, MSc. C. Psychol
Lucy Abraham, MSc. C. Psychol

on behalf of the PRO Consortium Depression Working Group

Patient Reported Outcomes and Person Centered Care in Mental Health
First Meeting on Patient Reported Outcomes in Mental Health
September 28-30, 2012 - Washington, DC
Conflict of Interest and Financial Disclosure

- Susan Ball, Ph.D.
  - Employee and shareholder of Eli Lilly and Company
- Cecilia Dedios, MSc. C. Psychol
  - Employee of Health Research Associates, a consulting firm, which has received funding from the PRO Consortium Depression Working Group
- Lucy Abraham, MSc. C.Psychol
  - Employee of Pfizer Ltd

This research was sponsored by the member firms of the Patient-Reported Outcome (PRO) Consortium Depression Working Group, which includes:

- Abbott Laboratories, Abbott Park, IL, USA; Bristol-Myers Squibb Company, Wallingford, CT, USA; Eli Lilly & Company, Indianapolis, IN, USA; Forest Laboratories, Inc., Jersey City, NJ, USA; Janssen Global Services, LLC*, Raritan, NJ, USA; Pfizer Inc., New York, NY, USA; Shire Development Inc., Wayne, PA, USA; Sunovion Pharmaceuticals Inc., Marlborough, MA, USA

- Critical Path Institute’s PRO Consortium is supported by grant No. U01FD003865 from the United States Food and Drug Administration and by Science Foundation Arizona under Grant No. SRG 0335-08.

*Janssen joined PRO Consortium Depression Working group subsequent to submission of abstract
Acknowledgments

• The authors would like to thank and acknowledge the following individuals for their contributions

• Critical Path Institute (C-Path) Staff:
  • Stephen Joel Coons, Theresa Flemming, Theresa Griffey, Karla Lehmann, Jason Lundy, Elizabeth Piault-Louis

• Depression Working Group member firm representatives:
  • **Abbott:** Nicholas Greco, Steven Haas, Christy Houle; **BMS:** Justin Doan;
  • **Lilly:** Susan Ball, Nicki Bush, Risa Hayes; **Forest:** Steven Blum, Maju Mathews, Abhilasha Ramasamy;
  • **Janssen:** Carol Jamieson; **Pfizer:** Lucy Abraham, Brendon Binneman, Philip Ninan (retired, non-member participant);
  • **Shire:** Linda Deal, Bryan Dirks, Manisha Madhoo, Dylan Supina;
  • **Sunovion:** Mariam Hassan, Kitty Rajagopalan

• Health Research Associates:
  • Don Bushnell, Cecilia Dedios, Mona Martin, Kelly McCarrier

• Expert Panel Members:
  • Linda L. Carpenter, MD - Butler Hospital/Brown University, Providence, RI
  • Michael E. Thase, MD - University of Pennsylvania, Philadelphia, PA
  • Madhukar H. Trivedi, MD - UT Southwestern Medical Center, Dallas, TX
About PRO Consortium

• C-Path, in cooperation with the FDA and the medical products industry, formed the Patient-Reported Outcome (PRO) Consortium in 2008 for the purpose of developing, evaluating, and qualifying PRO instruments with the FDA for use in clinical trials designed to evaluate the safety and efficacy of medical products.

• Current working groups include: Asthma, Cognition (mild cognitive impairment), Depression, Functional Dyspepsia, Irritable Bowel Syndrome, Non-Small Cell Lung Cancer, and Rheumatoid Arthritis.
The Depression Working Group is developing a new PRO instrument intended for use as a primary or key secondary endpoint in clinical trials for major depressive disorder to assess treatment efficacy from the patient’s perspective.

- Proposed instrument will be developed and validated following the FDA’s Drug Development Tools (DDT) qualification process [Draft guidance issued October 2010]
Background

- Depression is a disease whose experience includes a wide range of symptoms that are subjectively experienced by patients.
- However, efficacy of new treatments for MDD are typically evaluated using clinician assessment of symptoms, as defined by DSM-IV.
- Assessing symptoms from the patient's perspective is critical to fully evaluate a treatment’s risk/benefit ratio.
- While many MDD PRO tools exist, none have yet been accepted by regulators to evaluate treatment efficacy to support labelling.
- PRO Instrument Qualification requires a robust development process.
  - Literature review, qualitative interviews with patients, expert panel review, item generation, cognitive interviews, quantitative testing.
- As a first step towards seeking Regulatory Qualification of a PRO instrument to assess MDD symptoms in clinical trials, a systematic literature review was conducted to understand the patient’s perspective.
Aim of the Study

- To conduct a systematic literature review of published qualitative studies to understand the patient’s perspective on MDD, including the language patients use to talk about their condition, and the symptoms and disease impacts of greatest importance to them.
Methods

- **Systematic search of MEDLINE and PsychINFO**
  - **Primary Search Strategy**
    - Published in English language between 1991 and 2011
    - Peer-reviewed journal
    - Included community trials, case control studies, cohort studies, cross sectional studies, and qualitative studies
    - Studies had to include adults with diagnosed MDD
  - **Principal search terms (used alone and in combination)**
    - Major depression
    - Qualitative
    - Focus groups
    - Symptoms
    - Impacts
    - Patient attitude

- **Secondary Search Strategy**
  - Searched for ‘depression’ AND ‘qualitative’ since January 2009
Articles Identified

**PRIMARY SEARCH:**
- 177 articles identified
- 135 did not meet inclusion criteria
- Initial Abstract Review: 42 articles
- Complete Review: 13 articles
- Complete Review: 28 articles
- Final Literature Review: 19 articles

**SECONDARY SEARCH:**
- 608 articles identified
- 174 duplicates
- 406 did not meet inclusion criteria
- Initial Abstract Review: 28 articles
- Complete Review: 15 articles
- Complete Review: 28 articles

**Additional:**
- 9 dropped because of inadequate methods or focused on topics out of scope
Results: Concepts

- Emotional Symptoms
- Cognitive Symptoms
- Physical Symptoms
- Symptom-related Impacts
- Attributions of Cause
- Signs & Related Concepts

MDD Patient
## Symptoms of Depression: Emotional

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sadness/wanting to cry</td>
<td>“…when I got to work and got into the office, I would just sit there and cry.”</td>
</tr>
<tr>
<td>Guilt</td>
<td>“It’s embarrassing, you feel guilty, you feel weak”</td>
</tr>
<tr>
<td>Low self-esteem/self-efficacy</td>
<td>“Avoiding things, denying things, being more agitated and aggressive for no apparent reason”</td>
</tr>
<tr>
<td>Irritability/Anger</td>
<td>“It’s like a doorway that I know I can’t go through. I can’t do that to my parents….but I so much would just like to go to sleep and not wake up”</td>
</tr>
<tr>
<td>Helplessness/Hopelessness</td>
<td></td>
</tr>
<tr>
<td>Loneliness</td>
<td></td>
</tr>
<tr>
<td>Thoughts of death</td>
<td></td>
</tr>
</tbody>
</table>
# Symptoms of Depression: Physical

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Quotation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>“You feel as though you are walking through a bog in the fog, like you’re dragging your limbs around”</td>
</tr>
<tr>
<td>Sleep Disturbance</td>
<td>“For me, it’s the sleeping and the withdrawing [that] are a key that something’s wrong”</td>
</tr>
<tr>
<td>Bodily Aches &amp; Pains</td>
<td>“I get real, what I think is physical pain in my arms, my shoulders, my chest, I have headaches at the back of my head”</td>
</tr>
<tr>
<td>Heart Palpitations</td>
<td></td>
</tr>
<tr>
<td>Chest Pressure</td>
<td></td>
</tr>
<tr>
<td>Tingling in extremities</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal problems</td>
<td>“Everybody notices the weight loss. Everybody would be like, ‘Oh my God, what’s going on, what happened to you?’”</td>
</tr>
<tr>
<td>Weight Changes</td>
<td></td>
</tr>
</tbody>
</table>
### Symptoms of Depression: Cognitive

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Quote</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intrusive thoughts</td>
<td>“I will be released from all of this, all of these thoughts”</td>
</tr>
<tr>
<td>Desynchrony with environment</td>
<td>“I just started waking up early…two in the morning, wide awake …and you start worrying about the next day, and then… you worry about not sleeping. It’s a vicious cycle”</td>
</tr>
<tr>
<td>Cognitive Lethargy</td>
<td>“And my mental acuity also went.. it just scared the bee-gee-bees out of me, the lack of concentration I had at work”</td>
</tr>
</tbody>
</table>
### Disease-related Impacts

<table>
<thead>
<tr>
<th>Impacts</th>
<th>Quotes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social isolation, decreased social support, stigma</td>
<td>“you want to isolate yourself and you don’t actually want to be a part of all the normal things”</td>
</tr>
<tr>
<td>Relationship difficulties</td>
<td>“You don’t like to admit you’re a depressed person… there’s a negative view of someone with depression so you didn’t really let a lot of people know about it.”</td>
</tr>
<tr>
<td>Difficulties at work</td>
<td></td>
</tr>
<tr>
<td>Difficulties doing chores at home</td>
<td>“I get depressed and I don’t wanna do anything. If I didn’t have those symptoms I believe that I would be more active or more motivated to do more”</td>
</tr>
<tr>
<td>Decreased self-care</td>
<td></td>
</tr>
</tbody>
</table>
Signs and related concepts

- Concepts not easily defined by patients as symptoms, impacts or a cause of MDD

<table>
<thead>
<tr>
<th>Concept</th>
<th>Quote</th>
</tr>
</thead>
<tbody>
<tr>
<td>Significant life changes</td>
<td>“I had to actually leave the province, how’s that for embarrassment?”</td>
</tr>
<tr>
<td>Stress</td>
<td>“Extremely stressed at work and feeling physiological effects of the stress . . .”</td>
</tr>
<tr>
<td>General anxiety</td>
<td>“Because of being depressed I have made really stupid choices… I started having sex with heaps of different people, and drugs and alcohol were even worse. And then the depression came…”</td>
</tr>
<tr>
<td>Drug &amp; alcohol abuse</td>
<td></td>
</tr>
</tbody>
</table>

"Because of being depressed I have made really stupid choices… I started having sex with heaps of different people, and drugs and alcohol were even worse. And then the depression came…”
## Attributions of Cause

<table>
<thead>
<tr>
<th>Concept</th>
<th>Quotes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Life events, significant losses</td>
<td>“One of the things that affected me is the two children that died so close together…”</td>
</tr>
<tr>
<td></td>
<td>“I know a lot of black people that's depressed. Every black person I know is depressed”</td>
</tr>
<tr>
<td></td>
<td>“Poverty is the reason. If you can meet your needs, the problems will lessen”</td>
</tr>
</tbody>
</table>

- However, many patients reported limited or no understanding of the condition or its causes
  - Increased feelings of despair and impotence, anxiety, shame and guilt
  - Made it more likely that patients would blame external factors for their symptoms
Summary

- Depression is understood by patients in the terms of the symptoms, signs and disease-related impacts they are experiencing.
- Patients with depression focus their discourse more on their emotions as compared with other known clinical symptoms, such as cognitive and executive functioning symptoms.
- A range of concepts not easily defined as symptoms of depression or as disease-related impacts were also a substantial focus of patient discourse, suggesting that from the patient’s perspective comorbid symptoms are not distinctively derived from other conditions.
- Patients’ attributions of cause of depression should be investigated in detail during the qualitative interviews to provide important information on how they see the causes and impacts of their disease, but it may not be relevant for assessing illness severity.
Conclusions/Implications

- Patients' discourse focused primarily on their emotional symptoms suggesting these are the most burdensome and should be the focus of a PRO instrument.

- Impacts and attributions were more distal from symptoms, and while relevant to the understanding of the patient, these were supplementary to the core patient experience.

Implications for future research

- To assess efficacy from the patient's perspective, instruments for measuring clinical improvement in depression may need a more patient-centered foundation than used previously.
Next Steps for Depression WG

- Systematic Review of PRO instruments used to Assess Symptoms Associated with MDD
  - Being presented in the PROs: Mood & Anxiety Symposia

- Qualitative Concept Elicitation Interviews with Patients with MDD
  - to determine the adoption, adaptation, or creation of a PRO instrument fit for the purpose of assessing MDD treatment benefit in clinical trials
Articles Contributing to the Review

- Olliffe, JL.; Pgrodniczuk, JS.; Botteroff, JL.; Johnson, JL.; Hoyak, K. “You feel like you can’t live anymore”: Suicide from the perspectives of men who experience depression. (2010) Soc Sci & Med. doi:10.1016/j.socscimed.2010.03.057